Korro Bio, Inc. (KRRO)

Market Cap	141.96M -65.6%
Revenue (ttm)	2.38M -62.1%
Net Income	-106.64M
EPS	-8.88
Shares Out	14.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	153,051
Open	9.90
Previous Close	9.71
Day's Range	9.48 - 9.90
52-Week Range	5.20 - 55.89
Beta	2.36
Analysts	Strong Buy
Price Target	20.20 (+109.54%)
Est. Earnings	Nov 11, 2026

About KRRO

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe d...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 3, 2019
• Employees: 57
• Stock Exchange: Nasdaq
• Ticker Symbol: KRRO
• Website: https://www.korrobio.com

Financial Performance

In 2025, Korro Bio's revenue was $6.39 million, an increase of 181.46% compared to the previous year's $2.27 million. Losses were -$117.26 million, 40.3% more than in 2024.

Analyst Summary

According to 11 analysts, the average rating for KRRO stock is "Strong Buy." The 12-month stock price target is $20.2, which is an increase of 109.54% from the latest price.

Price Target

$20.2

(109.54% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 3, 2026

Data Sources Report a data error